India’s Contract Research, Development, and Manufacturing Organization (CRDMO) market is entering a major growth phase. With a projected compound annual growth rate (CAGR) of 15% through 2028 that is well above the global average of 9%, the sector is gaining traction as a key player in global pharmaceutical supply chains.
This rapid growth is driven by favorable government policies, increased demand for advanced therapies such as antibody-drug conjugates (ADCs) and cell and gene therapy (CGT), and a growing shift among global companies to diversify operations beyond China.
At the same time, Indian CRDMOs face critical challenges. Many are constrained by small-scale operations, a shortage of skilled talent, overdependence on imported raw materials, and inefficiencies across internal functions. Addressing these issues is essential for companies looking to scale sustainably and compete globally.
India’s CRDMO sector is growing fast, but capturing long-term value requires more than market momentum. Over the next two years, companies must focus on tightening operations: improving efficiency, digitizing core processes, and aligning governance to better manage variability and scale.
To sustain this growth, organizations need to build capabilities across R&D, analytics, and quality while making targeted investments in infrastructure and workforce productivity. The YCP Auctus Value Creation Framework helps CRDMOs identify where to focus across three key value levers.
Learn how your organization can apply the YCP Auctus Value Creation Framework to unlock short-term value, strengthen operations, and chart a course toward global competitiveness by downloading the full report.
